New taxane drug RP-001 enters human trials for Hard-to-Treat cancers
NCT ID NCT07504263
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial is testing a new chemotherapy drug called RP-001 in 66 adults with advanced solid tumors, including colorectal and pancreatic cancers. The main goals are to check safety, find the best dose, and see if the drug can shrink tumors. It is an open-label study, meaning everyone knows they are getting the experimental drug.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- RP-001 (a new type of taxane chemotherapy)
- What this could lead to
- If it works, this could provide a new chemotherapy option for people with advanced colorectal or pancreatic cancer that has stopped responding to other treatments.
- What could go wrong
- This is a very early, small trial (66 people) focused on safety and dosing. The drug may not shrink tumors or could cause serious side effects like other chemotherapies.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED MALIGNANCIES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A good Night's sleep: could a simple program ease Cancer's toll on rest?
- Can pancreatic Cancer's inflammatory footprint be stopped?
- Can a plasma beam stop colon polyps from coming back?
- A stitch in time: could a device make abdominal closure safer?
- Could sitting up make radiation therapy more comfortable?
- Can we predict chemo brain before it happens?